JP2024527028A - 抗ｌｉｇｈｔ抗体を用いて潰瘍性大腸炎を治療する方法 - Google Patents

抗ｌｉｇｈｔ抗体を用いて潰瘍性大腸炎を治療する方法 Download PDF

Info

Publication number
JP2024527028A
JP2024527028A JP2024504831A JP2024504831A JP2024527028A JP 2024527028 A JP2024527028 A JP 2024527028A JP 2024504831 A JP2024504831 A JP 2024504831A JP 2024504831 A JP2024504831 A JP 2024504831A JP 2024527028 A JP2024527028 A JP 2024527028A
Authority
JP
Japan
Prior art keywords
seq
nos
light
cdr
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024504831A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024527028A5 (enExample
Inventor
ギャリー エー． ニール，
Original Assignee
アヴァロ セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アヴァロ セラピューティクス， インコーポレイテッド filed Critical アヴァロ セラピューティクス， インコーポレイテッド
Publication of JP2024527028A publication Critical patent/JP2024527028A/ja
Publication of JP2024527028A5 publication Critical patent/JP2024527028A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2024504831A 2021-07-26 2022-07-25 抗ｌｉｇｈｔ抗体を用いて潰瘍性大腸炎を治療する方法 Pending JP2024527028A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163225675P 2021-07-26 2021-07-26
US63/225,675 2021-07-26
PCT/US2022/074106 WO2023009979A1 (en) 2021-07-26 2022-07-25 Methods of treating ulcerative colitis with anti-light antibodies

Publications (2)

Publication Number Publication Date
JP2024527028A true JP2024527028A (ja) 2024-07-19
JP2024527028A5 JP2024527028A5 (enExample) 2025-08-01

Family

ID=85087298

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024504831A Pending JP2024527028A (ja) 2021-07-26 2022-07-25 抗ｌｉｇｈｔ抗体を用いて潰瘍性大腸炎を治療する方法

Country Status (5)

Country Link
US (1) US20240158522A1 (enExample)
EP (1) EP4376888A4 (enExample)
JP (1) JP2024527028A (enExample)
CN (1) CN117940163A (enExample)
WO (1) WO2023009979A1 (enExample)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA021255B1 (ru) * 2006-08-28 2015-05-29 Киова Хакко Кирин Ко., Лимитед Антагонистические моноклональные антитела человека, специфичные в отношении light человека
WO2010111180A1 (en) * 2009-03-24 2010-09-30 Teva Biopharmaceuticals Usa, Inc. Humanized antibodies against light and uses thereof
US9592289B2 (en) * 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
WO2013148350A2 (en) * 2012-03-26 2013-10-03 Sanofi Anti-light antibody therapy for inflammatory bowel disease
CA2994719A1 (en) * 2015-08-21 2017-03-02 The Children's Hospital Of Philadelphia Methods of treating autoimmune conditions in patients with genetic variations in dcr3 or in a dcr3 network gene
PL3883606T3 (pl) * 2018-09-24 2023-11-27 Janssen Biotech, Inc. Bezpieczny i skuteczny sposób leczenia wrzodziejącego zapalenia jelita grubego przeciwciałami anty-il12/il23

Also Published As

Publication number Publication date
WO2023009979A1 (en) 2023-02-02
EP4376888A1 (en) 2024-06-05
CN117940163A (zh) 2024-04-26
EP4376888A4 (en) 2025-07-02
US20240158522A1 (en) 2024-05-16

Similar Documents

Publication Publication Date Title
EP1981539B1 (en) Treatment of metastatic breast cancer
RU2728710C2 (ru) Способы лечения нерентгенографического аксиального спондилоартрита, используя антагонисты интерлейкина-17 (il-17)
KR20140008305A (ko) Ｉｌ-１７ 길항제를 사용한 류마티스성 관절염의 치료 방법
KR20180063127A (ko) Il23 경로 바이오마커를 사용한, il23-길항제에 대한 임상 반응의 예측
JP2022515480A (ja) 掌蹠膿疱症の処置のための抗ｉｌ－３６ｒ抗体
JP2023527558A (ja) 関節リウマチのマーカー及び細胞の前兆
JP2024069230A (ja) 慢性回腸嚢炎の治療のための方法
JP2017528465A (ja) 乾癬性関節炎患者における構造的損傷の進行を阻害するためのｉｌ−１７アンタゴニストの使用
JP2021534195A (ja) 標的ＴＧＦ−β阻害によるトリプルネガティブ乳がんの処置
RU2530561C2 (ru) Способы лечения склеродермии
JP2017505763A (ja) 生物学的材料およびその治療用途
US20240368294A1 (en) Cd40l-specific tn3-derived scaffolds for use in the treatment and prevention of rheumatoid arthritis
EP4376888A1 (en) Methods of treating ulcerative colitis with anti-light antibodies
US20230279095A1 (en) Methods and Treatment for Adult-Onset Still's Disease and Systemic-Onset Juvenile Idiopathic Arthritis Involving Antibodies to IL-18
RU2822135C2 (ru) Способы лечения хронического резервуарного илеита
TWI865759B (zh) 涉及過量游離light之方法及治療
JP2025500352A (ja) Ｉｌ－１８に対する抗体を要する成人発症スチル病および全身発症型若年性特発性関節炎のための方法および治療
Granot et al. P109 Using baseline Peripheral blood mononuclear cell (PBMC) transcriptomics of Crohn Disease patients receiving Ustekinumab treatment as a tool to assess potential response at 1 year
JP2026514637A (ja) Ｉｌ－１７依存性病態のバイオマーカーに基づく治療および診断方法
HK40121853A (zh) 用抑制半乳糖凝集素-9的抗体治疗血液恶性肿瘤
TW202325730A (zh) 涉及ｉｌ－１８抗體之成人史迪爾氏症（ｓｔｉｌｌ＇ｓ ｄｉｓｅａｓｅ）及全身性幼年特發性關節炎之方法及治療
CN118076369A (zh) Cd40l特异性tn3衍生支架及其用于治疗和预防类风湿性关节炎的方法
Stephens et al. Efficacy and Safety of Certolizumab Pegol Do Not Appear To Be Affected by Neutralizing Antibodies in Patients with Crohn's Disease: 971
Keshav et al. PROTECT-1: A Prospective Randomized Trial of CCX282-B (Traficet-EN), a Novel Oral Therapy Targeting Chemokine Receptor 9 in Crohn's Disease: 972
HK40030423B (zh) 用於癌症的诊断和治疗方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250724

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250724